FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948406261> ?p ?o ?g. }

• W2948406261 endingPage "263" @default.
• W2948406261 startingPage "263" @default.
• W2948406261 abstract "New three-dimensionally-structured hybrid phospholipid vesicles, able to load clotrimazole in a high amount (10 mg/mL), were obtained for the first time in this work by significantly reducing the amount of water (≤10%), which was replaced with a mixture of glycerol and ethanol (≈90%). A pre-formulation study was carried out to evaluate the effect of both the composition of the hydrating medium and the concentration of the phospholipid on the physico-chemical properties of hybrid vesicles. Four different three-dimensionally-structured hybrid vesicles were selected as ideal systems for the topical application of clotrimazole. An extensive physico-chemical characterization performed using transmission electron microscopy (TEM), cryogenic transmission electron microscopy (cryo-TEM), 31P-NMR, and small-angle X-ray scattering (SAXS) displayed the formation of small, multi-, and unilamellar vesicles very close to each other, and was capable of forming a three-dimensional network, which stabilized the dispersion. Additionally, the dilution of the dispersion with water reduced the interactions between vesicles, leading to the formation of single unilamellar vesicles. The evaluation of the in vitro percutaneous delivery of clotrimazole showed an improved drug deposition in the skin strata provided by the three-dimensionally-structured vesicles with respect to the commercial cream (Canesten®) used as a reference. Hybrid vesicles were highly biocompatible and showed a significant antifungal activity in vitro, greater than the commercial cream Canesten®. The antimycotic efficacy of formulations was confirmed by the reduced proliferation of the yeast cells at the site of infection in vivo. In light of these results, clotrimazole-loaded, three-dimensionally-structured hybrid vesicles appear to be one of the most innovative and promising formulations for the treatment of candidiasis infections." @default.
• W2948406261 created "2019-06-14" @default.
• W2948406261 creator A5013483272 @default.
• W2948406261 creator A5020751334 @default.
• W2948406261 creator A5023387530 @default.
• W2948406261 creator A5036416654 @default.
• W2948406261 creator A5036635019 @default.
• W2948406261 creator A5056099299 @default.
• W2948406261 creator A5056970164 @default.
• W2948406261 creator A5070288537 @default.
• W2948406261 creator A5070967251 @default.
• W2948406261 creator A5090841375 @default.
• W2948406261 creator A5091806062 @default.
• W2948406261 date "2019-06-06" @default.
• W2948406261 modified "2023-10-10" @default.
• W2948406261 title "Optimization of Innovative Three-Dimensionally-Structured Hybrid Vesicles to Improve the Cutaneous Delivery of Clotrimazole for the Treatment of Topical Candidiasis" @default.
• W2948406261 cites W1186931653 @default.
• W2948406261 cites W1199514514 @default.
• W2948406261 cites W1600161348 @default.
• W2948406261 cites W1968911736 @default.
• W2948406261 cites W1973999112 @default.
• W2948406261 cites W1985041032 @default.
• W2948406261 cites W1989814732 @default.
• W2948406261 cites W1992684554 @default.
• W2948406261 cites W1993290417 @default.
• W2948406261 cites W1995660802 @default.
• W2948406261 cites W1999177915 @default.
• W2948406261 cites W1999251008 @default.
• W2948406261 cites W2000339087 @default.
• W2948406261 cites W2009113911 @default.
• W2948406261 cites W2014093866 @default.
• W2948406261 cites W2026916418 @default.
• W2948406261 cites W2029383767 @default.
• W2948406261 cites W2029601577 @default.
• W2948406261 cites W2033381869 @default.
• W2948406261 cites W2058009653 @default.
• W2948406261 cites W2058707261 @default.
• W2948406261 cites W2062280806 @default.
• W2948406261 cites W2063798555 @default.
• W2948406261 cites W2078062818 @default.
• W2948406261 cites W2085637276 @default.
• W2948406261 cites W2086420167 @default.
• W2948406261 cites W2089646575 @default.
• W2948406261 cites W2103716735 @default.
• W2948406261 cites W2105121917 @default.
• W2948406261 cites W2106405757 @default.
• W2948406261 cites W2119015040 @default.
• W2948406261 cites W2125848302 @default.
• W2948406261 cites W2133396078 @default.
• W2948406261 cites W2144149632 @default.
• W2948406261 cites W2157877237 @default.
• W2948406261 cites W2161034880 @default.
• W2948406261 cites W2169827263 @default.
• W2948406261 cites W2180248124 @default.
• W2948406261 cites W2300942687 @default.
• W2948406261 cites W2329048926 @default.
• W2948406261 cites W2331701419 @default.
• W2948406261 cites W2461561501 @default.
• W2948406261 cites W2470890763 @default.
• W2948406261 cites W2483628942 @default.
• W2948406261 cites W2587729310 @default.
• W2948406261 cites W2591223738 @default.
• W2948406261 cites W2765932238 @default.
• W2948406261 cites W2801375319 @default.
• W2948406261 cites W2898657245 @default.
• W2948406261 cites W4230878297 @default.
• W2948406261 doi "https://doi.org/10.3390/pharmaceutics11060263" @default.
• W2948406261 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6630241" @default.
• W2948406261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31174342" @default.
• W2948406261 hasPublicationYear "2019" @default.
• W2948406261 type Work @default.
• W2948406261 sameAs 2948406261 @default.
• W2948406261 citedByCount "16" @default.
• W2948406261 countsByYear W29484062612019 @default.
• W2948406261 countsByYear W29484062612020 @default.
• W2948406261 countsByYear W29484062612021 @default.
• W2948406261 countsByYear W29484062612022 @default.
• W2948406261 countsByYear W29484062612023 @default.
• W2948406261 crossrefType "journal-article" @default.
• W2948406261 hasAuthorship W2948406261A5013483272 @default.
• W2948406261 hasAuthorship W2948406261A5020751334 @default.
• W2948406261 hasAuthorship W2948406261A5023387530 @default.
• W2948406261 hasAuthorship W2948406261A5036416654 @default.
• W2948406261 hasAuthorship W2948406261A5036635019 @default.
• W2948406261 hasAuthorship W2948406261A5056099299 @default.
• W2948406261 hasAuthorship W2948406261A5056970164 @default.
• W2948406261 hasAuthorship W2948406261A5070288537 @default.
• W2948406261 hasAuthorship W2948406261A5070967251 @default.
• W2948406261 hasAuthorship W2948406261A5090841375 @default.
• W2948406261 hasAuthorship W2948406261A5091806062 @default.
• W2948406261 hasBestOaLocation W29484062611 @default.
• W2948406261 hasConcept C127413603 @default.
• W2948406261 hasConcept C130316041 @default.
• W2948406261 hasConcept C146088050 @default.
• W2948406261 hasConcept C171250308 @default.
• W2948406261 hasConcept C178790620 @default.
• W2948406261 hasConcept C185592680 @default.
• W2948406261 hasConcept C192562407 @default.

• next